January 12, 2018 07:15 AM ESTUpdated 08:51 AM
Startups

Jump­ing on an­ti-ag­ing band­wag­on, Y Com­bi­na­tor joins hunt for the $100B pill

Amber Tong

An­ti-ag­ing up­starts have been pop­ping up across the biotech land­scape, with a slate of biotechs rac­ing to­wards a mar­ket op­por­tu­ni­ty worth un­told bil­lions to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times